Emyria and Cann Group have announced a collaboration to seek accelerated registration of a unique, low-dose, CBD-only capsule with the Therapeutic Goods Administration (TGA) for sale over the counter in pharmacies.

Under the agreement, Emyria’s EMD-003 drug-development program will use Cann’s proprietary Gelpell microsphere technology as the basis for seeking a Schedule 3 registration for treating unmet needs in mental health.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Cann Group recently acquired the rights to the Gelpell technology through its acquisition of Satipharm

A recent internal analysis by Emyria revealed that more than 50% of its Emerald Clinics’ patients present with moderate to severe depression, anxiety and/or stress as measured by validated clinical assessments.

If successful, the collaboration will deliver a new, registered medicine to treat those patients.

A joint project committee will be formed to oversee the allocation of registration costs and the development of commercialisation agreements.

Cann Group recently acquired the rights to the Gelpell technology through its acquisition of the Satipharm Group, which has commercialised a CBD product utilising the technology.

Cann Group plans to incorporate manufacturing of the microsphere formulation in its new production facility currently under construction near Mildura.

The collaboration capitalises on a number of important milestones that have already been met: